Shopping Cart
- Remove All
Your shopping cart is currently empty
Lenzilumab (KB 003) is a humanized granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibody that directly binds to GM-CSF and prevents signaling through its receptor, and can be used to study COVID-19.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $183 | In Stock | |
| 5 mg | $463 | In Stock | |
| 10 mg | $742 | In Stock | |
| 25 mg | $1,120 | In Stock | |
| 50 mg | $1,490 | In Stock |
| Description | Lenzilumab (KB 003) is a humanized granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibody that directly binds to GM-CSF and prevents signaling through its receptor, and can be used to study COVID-19. |
| In vivo | Intraperitoneal injection of 10 mg/kg Lenzilumab once daily for 10 days improved its antitumor effect in NSG mice by inhibiting GM-CSF without impairing the cellular function of CAR-T and at the same time. [1] |
| Synonyms | KB003, KB 003 |
| Cas No. | 1229575-09-0 |
| Color | Transparent |
| Appearance | Liquid |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.